Home Biotechnology Calliditas Therapeutics
C

Calliditas Therapeutics

Profile managed by Bizz Id

Calliditas / Tarpeyo / Kinpeygo

Suecia 51-200 employees
Biotechnology Finished Dosage Forms (FDFs)
Claim this profile

Description

Swedish commercial-stage biopharmaceutical company headquartered in Stockholm. Develops Nefecon® (targeted-release budesonide), approved in the US as Tarpeyo® and in Europe as Kinpeygo® for IgA nephropathy. European commercialisation via STADA.

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free

We only use technical cookies that are necessary for the site to work and to keep you signed in. We do not use analytics or advertising cookies. Cookies